Konstantin Chernov, 1962, Development director of Chumakov Institute, has joined the team in 2013.
Prior to this, he has graduated from the Military Institute of foreign languages in Moscow and after discharge from active service in 2002 he works in pharmaceutical industry.
He has improved his managerial skills by graduating (with distinction) from the Academy of National Economy (Moscow) and Kingston University (London), obtaining MBA degree (2005).
As development director, he led departments responsible for strategic planning and development in national pharmaceutical manufacturing leader companies ‘Akrikhin” (2004-2007) and “Valenta” (2007 -2012).
Since his involvement into activities in Chumakov Institute he leads investment activity and supervises new areas of research and development. In 2014-2016 he led the reunification process of Chumakov Institute and Chumakov manufacturing site. Thus, the integrity of research, development, and manufacturing chain has been restored and now Institute is able seamlessly move on the road of development of new products – from fundamental and applied research to finished forms manufacturing and registration.
His primary mission at the moment – bring in investment to upscale manufacturing capacity of the site in regard to two potential blockbuster products recently developed by Chumakov Institute – Sabin poliovaccine and coronavirus CoviVac vaccine.
Next prospective area of research he leads now is applicability of live viruses for treatment of malignant tumors.
He is also responsible for international activity of the Institute, including supervision of XFEL (X-ray Free Electron Laser, Hamburg) collaboration project.